Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
On this episode, Andrew Wei, MBBS, PhD, goes especially in depth regarding venetoclax plus azacitidine combination.
MDS-related gene mutations and number of mutations did not correlate with worse outcomes.
Researchers have validated a new molecular prognostic risk signature for patients with AML who received HMAs and venetoclax.
The phase II component of this clinical trial evaluating ziftomenib for heavily pretreated AML is in progress.
Pivekimab sunirine showed single-agent activity across multiple doses in the treatment of patients with AML.
Advertisement
Translational analyses in a phase Ib/II study identified several potentially actionable mechanisms behind relapsed disease.
A study found particular mutations to be associated with worse overall survival and greater likelihood of MRD positivity.
Interim analysis from a phase I/II trial found that a majority of the patients evaluable for MRD had no detectable disease.
Length of venetoclax dosing and prior chemotherapy exposure were associated with prolonged hematological recovery.
The phase III SIERRA trial compared Iomab-B-led allogeneic HSCT with conventional care in older patients with AML.
The prognostic significance of mNPM1 MRD is greatest in AML patients with concomitant FLT3-ITD.
Some interventions such as PARP inhibitors can cause adverse events, but others such as HSCT can benefit patients.
Sorafenib, a FLT3 inhibitor, led to significantly improved survival compared with placebo in patients with AML.
Quizartinib significantly improves long-term survival in FLT3-ITD+ AML by achieving deep and sustained reductions in MRD.
Combining HMAs with venetoclax significantly improves remission rates and survival but requires more healthcare resources.
SLC40A1 mRNA levels were significantly higher in AML patients compared with controls and were associated with poorer OS.
Achieving complete hematologic recovery before subsequent treatment cycles is associated with improved survival outcomes.
Combining genomic markers and clinical parameters increased the accuracy of predicting treatment response in pediatric ALL.
Lisaftoclax yielded promising progression free survival in elderly patients and in those with relapsed or refractory disease.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.